Hydrogen-rich Water for Molecular and Phenotypic Biomarkers of Aging

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effects of six-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in men and women aged 70 years and over.

Official Title
-----------------
The Effects of Six-month Hydrogen-rich Water Intake on Molecular and Phenotypic Biomarkers of Aging in Men and Women Aged 70 Years and Over: a Randomized-controlled Trial

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Dietary Supplement: Hydrogen-rich water
* Other: Control Water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 70 years Free of acute disorders Exclusion Criteria: History of dietary supplement use during the past 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hydrogen-rich water<br>Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.) 8 ppm of hydrogen Administered one dose two times per day on an empty stomach in the morning and at the evening | Dietary Supplement: Hydrogen-rich water<br>* A tablet that produces hydrogen dissolved in a glass of water<br>|
| Placebo Comparator: Control water<br>Tap water 0 ppm of hydrogen Administered one dose two times per day on an empty stomach in the morning and at the evening | Other: Control Water<br>* A glass of tap water<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in TeloTAGGG Telomerase PCR activity in serum | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in DNA methylation | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in blood concentration of advanced glycation end product | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in lipid peroxidation | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in serum FGF21 | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in serum TET2 | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in ADAS-Cog score (0-70 scale, higher scores indicating greater cognitive impairment) | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in facial wrinkling (0-100 scale; higher scores mean worse outcome) | Baseline vs. 6 months | Baseline vs. 6 months post-intervention | 
| Change in maximal oxygen uptake estimated by step-in-place test | Baseline vs. 6 months | Baseline vs. 6 months post-intervention |